Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Name: Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner
License: Public Domain

Jonsson Comprehensive Cancer Center

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

clinical stage i hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc (american joint committee on cancer) v8, clinical stage ii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage iii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, human papillomavirus positive, oropharyngeal squamous cell carcinoma, p16 positive neoplastic cells present

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 432900
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.